Letter to the editorDifferent bile concentration of micafungin and itraconazole in a patient with candidal cholecystitis
Section snippets
Conflict of interest
None of the authors declare a conflict of interest.
References (9)
- et al.
Biliary candida infections in primary sclerosing cholangitis
J Hepatol
(2006) - et al.
Involvement of multidrug resistance-associated protein 2 (ABCC/2Mrp2) in biliary excretion of micafungin in rats
Life Sci
(2008) - et al.
Candida infections in surgical patients
Ann Surg
(1983) - et al.
Guidelines for treatment of candidasis
Clin Infect Dis
(2004)
Cited by (5)
Biliary amphotericin B pharmacokinetics and pharmacodynamics in critically ill liver transplant recipients receiving treatment with amphotericin B lipid formulations
2015, International Journal of Antimicrobial AgentsCitation Excerpt :According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST), the MIC breakpoint for fluconazole susceptibility is ≤2 mg/L for C. albicans, C. krusei and C. tropicalis and ≤0.002 mg/L for C. glabrata. Caspofungin reached a biliary concentration of 1.0 mg/L after a 70 mg infusion, and micafungin reached 1.9 mg/L after administration of 150 mg [22,23]. The EUCAST breakpoint for susceptibility is ≤0.016 mg/L for C. albicans and ≤0.03 mg/L for C. glabrata.
Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole
2013, Clinica Chimica ActaCitation Excerpt :There is little literature on the urinary excretion of ITZ metabolites. ITZ is also excreted in bile; however, its concentration in bile was reported to be lower than 10 μg/l [14]. Prolonged ITZ therapy has been reported to lead to acquired resistance by Aspergillus fumigatus [15].
Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
2018, Clinical PharmacokineticsIn vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats
2010, Drug Metabolism and Disposition